(QURE) Uniqure - Overview
Stock: Gene Therapy, Hemophilia B, Huntingtons Disease, Epilepsy, ALS
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 141% |
| Relative Tail Risk | -38.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.84 |
| Alpha | 43.75 |
| Character TTM | |
|---|---|
| Beta | 0.968 |
| Beta Downside | 2.523 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.97% |
| CAGR/Max DD | 0.08 |
Description: QURE Uniqure January 25, 2026
uniQure N.V. (NASDAQ: QURE) is a Dutch-based biotech that focuses on gene-therapy solutions for rare, high-unmet-need diseases. Its FDA-approved product, HEMGENIX, delivers a functional factor IX gene to hemophilia B patients, reducing bleeding events and the need for regular factor infusions.
Beyond HEMGENIX, the company’s pipeline centers on several Phase I/II programs: AMT-130 for Huntington’s disease (currently enrolling 45 patients across U.S. and EU sites), AMT-260 for mesial temporal lobe epilepsy, AMT-162 for SOD-1-linked ALS, and AMT-191 for Fabry disease. As of the most recent Q2 2025 filing, uniQure reported cash and short-term investments of $312 million, a net loss of $44.8 million for the quarter, and HEMGENIX net sales of $31 million, reflecting modest commercial traction while the pipeline advances.
The gene-therapy sector is expanding at a projected 13 % CAGR through 2030, driven by increasing FDA approvals and growing payer acceptance of one-time curative treatments. uniQure’s reliance on U.S. reimbursement policy for HEMGENIX and its licensing partnership with Apic Bio for SOD-1 ALS therapy are key economic levers that could materially affect future cash flow. If you’re evaluating the upside of QURE’s pipeline relative to sector growth, a quick look at ValueRay’s analyst scorecard may surface additional quantitative insights worth exploring.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -235.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA 12.61 > 1.0 |
| NWC/Revenue: 3908 % < 20% (prev 1374 %; Δ 2534 % < -1%) |
| CFO/TA -0.17 > 3% & CFO -153.2m > Net Income -235.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.5m) vs 12m ago 20.11% < -2% |
| Gross Margin: 88.13% > 18% (prev 0.07%; Δ 8806 % > 0.5%) |
| Asset Turnover: 2.05% > 50% (prev 4.43%; Δ -2.37% > 0%) |
| Interest Coverage Ratio: -2.61 > 6 (EBITDA TTM -146.3m / Interest Expense TTM 62.3m) |
Altman Z'' -3.76
| A: 0.69 (Total Current Assets 716.2m - Total Current Liabilities 100.6m) / Total Assets 888.4m |
| B: -1.45 (Retained Earnings -1.29b / Total Assets 888.4m) |
| C: -0.21 (EBIT TTM -162.4m / Avg Total Assets 767.1m) |
| D: -2.04 (Book Value of Equity -1.35b / Total Liabilities 659.6m) |
| Altman-Z'' Score: -3.76 = D |
Beneish M -4.00
| DSRI: 1.32 (Receivables 3.88m/5.32m, Revenue 15.8m/28.6m) |
| GMI: 0.08 (GM 88.13% / 7.15%) |
| AQI: 0.74 (AQ_t 0.16 / AQ_t-1 0.22) |
| SGI: 0.55 (Revenue 15.8m / 28.6m) |
| TATA: -0.09 (NI -235.1m - CFO -153.2m) / TA 888.4m) |
| Beneish M-Score: -4.16 (Cap -4..+1) = AAA |
What is the price of QURE shares?
Over the past week, the price has changed by +12.90%, over one month by +14.97%, over three months by -6.76% and over the past year by +58.24%.
Is QURE a buy, sell or hold?
- StrongBuy: 9
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the QURE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.6 | 108.9% |
| Analysts Target Price | 53.6 | 108.9% |
| ValueRay Target Price | 27.5 | 7.1% |
QURE Fundamental Data Overview February 03, 2026
P/S = 89.8525
P/B = 6.1871
Revenue TTM = 15.8m USD
EBIT TTM = -162.4m USD
EBITDA TTM = -146.3m USD
Long Term Debt = 51.9m USD (from longTermDebt, last quarter)
Short Term Debt = 3.91m USD (from shortTermDebt, last quarter)
Debt = 66.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -530.9m USD (from netDebt column, last quarter)
Enterprise Value = 787.2m USD (1.42b + Debt 66.2m - CCE 694.2m)
Interest Coverage Ratio = -2.61 (Ebit TTM -162.4m / Interest Expense TTM 62.3m)
EV/FCF = -5.12x (Enterprise Value 787.2m / FCF TTM -153.6m)
FCF Yield = -19.52% (FCF TTM -153.6m / Enterprise Value 787.2m)
FCF Margin = -975.3% (FCF TTM -153.6m / Revenue TTM 15.8m)
Net Margin = -1493 % (Net Income TTM -235.1m / Revenue TTM 15.8m)
Gross Margin = 88.13% ((Revenue TTM 15.8m - Cost of Revenue TTM 1.87m) / Revenue TTM)
Gross Margin QoQ = 89.25% (prev 87.53%)
Tobins Q-Ratio = 0.89 (Enterprise Value 787.2m / Total Assets 888.4m)
Interest Expense / Debt = 25.28% (Interest Expense 16.7m / Debt 66.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -128.3m (EBIT -162.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.12 (Total Current Assets 716.2m / Total Current Liabilities 100.6m)
Debt / Equity = 0.29 (Debt 66.2m / totalStockholderEquity, last quarter 228.7m)
Debt / EBITDA = 3.63 (negative EBITDA) (Net Debt -530.9m / EBITDA -146.3m)
Debt / FCF = 3.46 (negative FCF - burning cash) (Net Debt -530.9m / FCF TTM -153.6m)
Total Stockholder Equity = 62.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.65% (Net Income -235.1m / Total Assets 888.4m)
RoE = -373.7% (Net Income TTM -235.1m / Total Stockholder Equity 62.9m)
RoCE = -141.5% (out of range, set to none) (EBIT -162.4m / Capital Employed (Equity 62.9m + L.T.Debt 51.9m))
RoIC = -112.0% (out of range, set to none) (NOPAT -128.3m / Invested Capital 114.6m)
WACC = 9.95% (E(1.42b)/V(1.48b) * Re(9.48%) + D(66.2m)/V(1.48b) * Rd(25.28%) * (1-Tc(0.21)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.60%
Fair Price DCF = unknown (Cash Flow -153.6m)
EPS Correlation: 12.39 | EPS CAGR: 20.48% | SUE: 2.37 | # QB: 1
Revenue Correlation: -10.57 | Revenue CAGR: -51.92% | SUE: -0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.79 | Chg30d=-0.015 | Revisions Net=+2 | Analysts=7
EPS next Year (2026-12-31): EPS=-2.78 | Chg30d=-0.116 | Revisions Net=+2 | Growth EPS=+16.8% | Growth Revenue=+238.4%